Améliorations pharmacologiques apportées par les nouveaux anticoagulants oraux

ANSM, Les anticoagulants en France en 2012 : État des lieux et surveillance. Juillet 2012. Li, 2004, Identification of the gene for vitamin K epoxide reductase, Nature, 427, 541, 10.1038/nature02254 Blech, 2008, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metab Dispos, 36, 386, 10.1124/dmd.107.019083 Lang, 2009, In vitro metabolism of rivaroxaban, an oral direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans, Drug Metab Dispos, 37, 1046, 10.1124/dmd.108.025551 Raghavan, 2008, Apixaban metabolism and pharmacokinetics after oral administration to humans, Drug Metab Dispos, 37, 74, 10.1124/dmd.108.023143 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Leil, 2010, Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose, Clin Pharmacol Ther, 88, 375, 10.1038/clpt.2010.106 Lehr, 2012, Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation, J Clin Pharmacol, 52, 1373, 10.1177/0091270011417716 Stangier, 2008, Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment, J Clin Pharmacol, 48, 1411, 10.1177/0091270008324179 Limdi, 2009, Kidney function influences warfarin responsiveness and hemorrhagic complications, J Am Soc Nephrol, 20, 912, 10.1681/ASN.2008070802 Trocóniz, 2007, Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery, J Clin Pharmacol, 47, 371, 10.1177/0091270006297228 CHMP. ELIQUIS, INN-apixaban. EMEA, editor. http://ec.europa.eu/health/documents/communityregister/2011/20110518102349/anx_102349_fr.pdf. 2011. p. 1–29. CHMP. Pradaxa, INN-dabigatran etexilate. EMEA, editor. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. 2008 Apr. 10. 1–36 CHMP. Xarelto, INN-Rivaroxaban. EMEA, editor. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf. 2008. p. 1–56. ANSM, Tésaurus des interactions médicamenteuses, Décembre 2012. Verstuyft, 2012, A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy, Clin Pharmacokinet, 51, 41, 10.2165/11595560-000000000-00000 Wadelius, 2009, The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, 113, 784, 10.1182/blood-2008-04-149070 Pare, 2013, Genetic determinants of dabigatran plasma levels and their relation to bleeding, Circulation, 127, 1404, 10.1161/CIRCULATIONAHA.112.001233 Delavenne, 2013, Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study, J Pharm Biomed Anal, 78–79, 150, 10.1016/j.jpba.2013.02.007 Delavenne, 2012, UPLC MS/MS assay for routine quantification of dabigatran – A direct thrombin inhibitor in human plasma, J Pharm Biomed Anal, 58, 152, 10.1016/j.jpba.2011.09.018 Schiele, 2013, A specific antidote for dabigatran: functional and structural characterization, Blood, 121, 3554, 10.1182/blood-2012-11-468207 Lu, 2013, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, 19, 446, 10.1038/nm.3102